ArticleThoracic cancer2026
Efficacy of Osimertinib in Patients With Postoperative Recurrent Non-Small-Cell Lung Cancer Harboring Sensitizing EGFR Mutations.
Article in Thoracic cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe efficacy of osimertinib in patients with postoperative recurrent non-small-cell lung cancer (NSCLC) compared to those with Stage IV NSCLC harboring epidermal growth factor receptor (EGFR) mutations remains unclear.
methodsThis study evaluated the efficacy of osimertinib in patients with postoperative recurrent EGFR-mutated NSCLC. We retrospectively evaluated patients with NSCLC harboring EGFR mutations (exon 19 deletion or L858R mutation) who received osimertinib between September 2018 and July 2022 at a single institution. The efficacy of osimertinib was compared between patients with postoperative recurrent NSCLC (postoperative group) and those with Stage IV NSCLC (Stage IV group).
resultsAmong a total of 172 patients treated with osimertinib, 52 were classified into the postoperative group and 120 into the Stage IV group. The response rate (58.1% vs. 61.8%, p = 0.836) and progression-free survival (hazard ratio [HR]: 0.854, 95% confidence interval [CI]: 0.558-1.306, p = 0.465) were not significantly different between the postoperative and Stage IV groups. Overall survival (OS) was significantly longer in the postoperative group than in the Stage IV group (median: 39.2 months and 28.5 months, respectively; HR: 0.521, 95% CI: 0.293-0.927, p = 0.024). In the multivariable analysis of OS, postoperative recurrent disease and performance status were independent favorable prognostic factors.
conclusionsPostoperative recurrent disease was an independent favorable prognostic factor in patients with NSCLC harboring EGFR mutations treated with osimertinib.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.